Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
